Skip links

News

molecular-‘super-glue’-shows-promise-of-cancer-drug-discovery-platform

Molecular ‘super-glue’ shows promise of cancer drug discovery platform

(MEMPHIS, Tenn. – January 16, 2024) Today, St. Jude Children’s Research Hospital scientists published their work on SJ3149, a compound with broad activity against many cancer types, particularly acute myeloid leukemia (AML). SJ3149 sticks to the cancer-related protein casein kinase 1 alpha (CK1α), leading to
study-pinpoints-breast-cancer-‘cells-of-origin’-in-high-risk-women

Study pinpoints breast cancer ‘cells-of-origin’ in high-risk women

Australian scientists have pinpointed likely ‘cells-of-origin’, the source cells that can grow into breast cancer, in women carrying a faulty BRCA2 gene who are at high risk of developing the disease. Credit: Must credit Dr Bianca Capaldo, WEHI Australian scientists have pinpointed likely ‘cells-of-origin’, the
reductive-carboxylation-of-glutamine-as-a-potential-target-in-aml

Reductive carboxylation of glutamine as a potential target in AML

“Identification and validation of novel and targetable metabolic weaknesses in AML is ongoing.” Credit: 2023 Roma et al. “Identification and validation of novel and targetable metabolic weaknesses in AML is ongoing.” BUFFALO, NY- January 16, 2024 – A new editorial paper was published in Oncotarget’s
special-rna-suppresses-the-formation-of-breast-cancer-cells

Special RNA suppresses the formation of breast cancer cells

Breast cancer is the most common cancer in women. The development of breast cancer often originates from epithelial cells in the mammary gland – the very cells that specialise in milk production during and after pregnancy. A team of researchers from Friedrich Schiller University Jena
osimertinib-resistance-and-egfr-mutations-in-nsclc-treatment

Osimertinib Resistance and EGFR Mutations in NSCLC Treatment

The presence of the T790M mutation during first or second-generation EGFR-TKI treatments is observed in 50-60% of patients. This mutation hinders the drug’s binding to the mutant EGFR protein. Osimertinib, however, can covalently bind to the T790M and cysteine-797 (C797) residue at the protein’s ATP
Explore
Drag